{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '5. Investigator-assessed presumptive PD events that are not confirmed by the IRC will have', 'their PFS censored at the time of treatment discontinuation.', 'Patients in the Vd Arm who are able to tolerate continued bortezomib treatment will be allowed', 'to cross over to SVdX treatment.', 'Patients in the Vd Arm who have significant tolerability issues with bortezomib (ie, are unable to', 'tolerate any continued bortezomib treatment, eg, due to Grade >2 peripheral neuropathy', 'or Grade >2 peripheral neuropathy with pain) will be allowed to cross over to SdX treatment.', 'Patients who do not elect to cross over to SVdX or SdX from the Vd Arm will discontinue', 'treatment, proceed to the EoT Visit, and be followed for survival.', '6.3.', 'Data Safety Monitoring Board', 'An independent Data Safety Monitoring Board (DSMB) will be set up for the study to review', 'safety data for this study. The DSMB is made up of a group of individuals with pertinent', 'expertise that reviews, on a predetermined schedule, safety data from this clinical study. It is the', \"DSMB's responsibility to weigh risks and benefits throughout the study's duration. The DSMB\", 'will provide oversight and safety monitoring of the study in compliance with applicable', 'regulations, legislation and associated guidance materials for the nature of the study.', 'As appropriate, the DSMB will provide recommendations to the Sponsor regarding continuation,', 'modification, or discontinuation of the study based on its assessment of the reviewed safety data.', 'This DSMB will be composed of 4 voting members (3 oncologists and an independent', 'statistician) who will review safety data from the study. The DSMB membership, functioning,', 'and procedures are described in the DSMB charter.', '6.4.', 'Independent Review Committee', 'An IRC will be formed to review MM disease assessment data for this study, to independently', 'assess disease response and time of PD. PD based on site generated MM disease assessment data', 'must be confirmed by the IRC prior to discontinuing treatment from either arm (unless medically', 'contraindicated). PD as a result of plasmacytoma(s) or bone lesion(s) will be reviewed by the', 'IRC and results will be compared with baseline assessments. IRC confirmation of PD is required', 'for all patients and, for those patients in the Vd Arm, confirmation is required prior to initiation', 'of SVdX/SdX treatment in the crossover (Section 6.2). The IRC will review data (generated by', 'the local and central laboratory) that will be used for the final analysis of the primary endpoint.', \"The IRC's assessments of PFS will be used as the basis for the evaluation of the primary\", 'endpoint. The IRC membership, functioning, and procedures (including resolution of any', 'disagreements with Investigators regarding MM disease assessments) are described in the IRC', 'charter.', 'Confidential', 'Page 50', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '7.', 'STUDY POPULATION SELECTION', '7.1.', 'Study Population', 'This study will enroll patients >18 years of age with RRMM who have received 1 to 3 prior', 'anti-MM regimens and who meet all of the inclusion criteria and none of the exclusion criteria.', 'Inclusion/exclusion criteria will be assessed during Screening.', '7.2.', 'Inclusion Criteria', 'Patients must meet all of the following inclusion criteria to be eligible to enroll in this study:', '1. Histologically confirmed MM with measurable disease per IMWG guidelines as defined', 'by at least 1 of the following:', 'a.', 'Serum M-protein >0.5 g/dL (>5 g/L) by serum protein electrophoresis (SPEP) or for', 'immunoglobulin (Ig) A myeloma, by quantitative serum IgA levels; or', 'b. Urinary M-protein excretion at least 200 mg/24 hours; or', 'c.', 'Serum FLC>100 mg/L, provided that the serum FLC ratio is abnormal (normal FLC', 'ratio: 0.26 to 1.65).', '2. Had at least 1 prior anti-MM regimen and no more than 3 prior anti-MM regimens.', 'Induction therapy followed by stem cell transplant and consolidation/maintenance', 'therapy will be considered as 1 anti-MM regimen.', \"3. Documented evidence of progressive MM (based on the Investigator's determination\", 'according to the IMWG response criteria) on or after their most recent regimen.', '4. Prior treatment with bortezomib or other PI is allowed, provided all of the following', 'criteria are met:', '-', 'Best response achieved with prior bortezomib at any time was > PR and with the', 'last PI therapy (alone or in combination) was > PR, AND', '- Participant did not discontinue bortezomib due to Grade >3 related toxicity, AND', '- Must have had at least a 6-month PI-treatment-free interval prior to C1D1 of', 'study treatment.', '5. Must have an ECOG Status score of 0, 1, or 2.', '6. Written informed consent in accordance with federal, local, and institutional guidelines.', '7. Age >18 years.', '8. Resolution of any clinically significant non-hematological toxicities (if any) from', 'previous treatments to Grade <1 by C1D1. Patients with chronic, stable Grade 2', 'non-hematological toxicities may be included following approval from the Medical', 'Monitor.', '9. Adequate hepatic function within 28 days prior to C1D1:', \"a. Total bilirubin <1.5 X upper limit of normal (ULN) (except patients with Gilbert's\", 'syndrome who must have a total bilirubin of <3 X ULN), and', 'Confidential', 'Page 51', 'Version 4.0']\n\n###\n\n", "completion": "END"}